


## Industry Satellite Symposium

# “Are **Biosimilars** the key to **Breaking Barriers** for **Global Healthcare Access** and **Sustainability**? A look at redefining the future”

 DATE  
13<sup>th</sup> March

 TIME  
12.00-13.30

 PLACE  
Auditorium 10

Time 	Topic 	Speaker 
12:00 - 12:05	Welcome note and opening remarks	<b>Rahul Kapur</b> Head Medical Affairs-EM and COE, Biocon Biologics Limited (India)
12:05 - 12:20	<b>Missed opportunity?</b> <i>Have Biosimilars been the Game-Changer we need</i>	<b>Uwe Gudat</b> Chief Medical Officer, Biocon Biologics (Switzerland)
12:20 - 12:35	<b>Myth or Reality</b> Are we letting fear outpace science?	<b>Elena Wolff-Holz</b> Global Head-Clinical Development, Biocon Biologics (Germany)
12:35 - 12:50	<b>From Complexity to Clarity</b> Onchemo’s impact on Oncology workflows	<b>Hartmut Link</b> Professor of Medicine, External Faculty, Hannover Medical School (Germany) Former Head Dept. Hematology and Oncology, Academic Hospital Kaiserslautern (Germany)
12:50 - 13:05	<b>Focussing on what matters</b> Evolving framework for Biosimilars approval	<b>Arlene Wolny</b> Head of Global Regulatory Affairs, Biocon Biologics (US)
13:05 - 13:25	<b>Biosimilars in action - The Road Ahead</b> Panel Discussion	Moderator - <b>Uwe Gudat</b> Panel - <b>Arlene Wolny</b> <b>Elena Wolff-Holz</b> <b>Hartmut Link</b>
13:25 - 13:30	Closing remarks and call to action	<b>Rahul Kapur</b> Head Medical Affairs-EM and COE, Biocon Biologics Limited (India)